We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+12.33%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.23B
AUM Growth
-$160M
Cap. Flow
-$204M
Cap. Flow %
-3.9%
Top 10 Hldgs %
34.65%
Holding
139
New
8
Increased
26
Reduced
20
Closed
24

Top Buys

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$97.9M
2
UNH icon
UnitedHealth
UNH
+$60M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$51.5M
4
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$37.9M
5
THC icon
Tenet Healthcare
THC
+$26.7M

Top Sells

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$108M
2
ARGX icon
argenx
ARGX
+$94.8M
3
ABBV icon
AbbVie
ABBV
+$80.5M
4
PFE icon
Pfizer
PFE
+$57.8M
5
GH icon
Guardant Health
GH
+$53.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.41%
2 Miscellaneous 1.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GDRX icon
101
GoodRx Holdings
GDRX
$1.2B
$1.81M 0.03%
+387,567
New +$1.91M
EYPT icon
102
EyePoint Inc
EYPT
$326M
$1.71M 0.03%
487,642
-483,218
-50% -$2.13M
HELP
103
Cybin Inc
HELP
$970M
$1.65M 0.03%
141,745
-133,350
-48% -$2.2M
PYXS icon
104
Pyxis Oncology
PYXS
$280M
$1.14M 0.02%
848,252
– –
HARP
105
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$1.1M 0.02%
151,650
-150,941
-50% -$1.27M
OMIC
106
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$1.09M 0.02%
18,023
– –
BOLT icon
107
Bolt Biotherapeutics
BOLT
$8.23M
$1M 0.02%
38,553
– –
EPIX
108
DELISTED
ESSA Pharma
EPIX
$921K 0.02%
365,300
-275,345
-43% -$790K
MACK
109
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$843K 0.02%
+73,600
New +$606K
SYRE icon
110
Spyre Therapeutics
SYRE
$7.95B
$809K 0.02%
71,889
– –
HLSQ
111
Tessera Defense and Homeland Security Inc.
HLSQ
$2.65M
$525K 0.01%
1,481
– –
GLUE icon
112
Monte Rosa Therapeutics
GLUE
$1.1B
$208K ﹤0.01%
27,369
-90,086
-77% -$750K
ABBV icon
113
AbbVie
ABBV
$463B
– –
-600,000
Closed -$80.5M
ALNY icon
114
Alnylam Pharmaceuticals
ALNY
$32.3B
– –
-250,500
Closed -$50.1M
BNR
115
Burning Rock Biotech
BNR
$123M
– –
-128,282
Closed -$3.07M
DNTH icon
116
Dianthus Therapeutics
DNTH
$5.83B
– –
-140,685
Closed -$3.17M
DYN icon
117
Dyne Therapeutics
DYN
$3.38B
– –
-220,400
Closed -$2.8M
GH icon
118
Guardant Health
GH
$23.8B
– –
-992,400
Closed -$53.4M
HRTX icon
119
Heron Therapeutics
HRTX
$59.6M
– –
-1,123,000
Closed -$4.74M
KALV
120
DELISTED
KalVista Pharmaceuticals
KALV
– –
-1,042,000
Closed -$15.1M
LLY icon
121
CALL
Eli Lilly
LLY
$1.01T
– –
-15,000
Closed -$4.85M
LUNG icon
122
Pulmonx
LUNG
$84.6M
– –
-435,000
Closed -$7.25M
MGTX icon
123
MeiraGTx Holdings
MGTX
$1.21B
– –
-2,108,143
Closed -$17.7M
MIRM icon
124
Mirum Pharmaceuticals
MIRM
$6.1B
– –
-521,891
Closed -$11M
IMDX
125
Insight Molecular Diagnostics
IMDX
$129M
– –
-94,138
Closed -$1.37M
2 3 4
5
6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q4 2022 Portfolio in Review

As of Q4 2022, OrbiMed held 139 positions worth $5.23B, down 3% from $5.39B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed withdrew a net $204M in Q4 2022, closing 24 positions and reducing 20 holdings. Its most notable exit was Tricida, Inc. Common Stock, an estimated $108M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $19.5M.

  • OrbiMed's largest Q4 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 171,000 shares worth $19.5M.
  • OrbiMed added most to Disc Medicine in Q4 2022, an estimated $97.9M increase.
  • OrbiMed's biggest Q4 2022 reduction was argenx, cutting an estimated $94.8M.
  • OrbiMed fully exited Tricida, Inc. Common Stock in Q4 2022, selling an estimated $108M.
  • OrbiMed's ten largest holdings make up 35% of its $5.23B portfolio in Q4 2022.
  • OrbiMed opened 8 new positions and closed 24 in Q4 2022.
  • OrbiMed's portfolio value fell 3% quarter-over-quarter to $5.23B.

Based on OrbiMed's 13F filing for Q4 2022, filed 14 Feb 2023.